about
Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study.Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study.Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinomaOverinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care.Multiple mechanisms limit the accumulation of unesterified cholesterol in the small intestine of mice deficient in both ACAT2 and ABCA1.Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer.Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial.Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters.Review article: the global emergence of Helicobacter pylori antibiotic resistance.A functional, genome-wide evaluation of liposensitive yeast identifies the "ARE2 required for viability" (ARV1) gene product as a major component of eukaryotic fatty acid resistanceSustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse.Successful combined liver/kidney transplantation from a donor with Pompe disease.Magnetic resonance elastography identifies fibrosis in adults with alpha-1 antitrypsin deficiency liver disease: a prospective study.Contemplating cognitive enhancement in medical students and residents.Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.Paraneoplastic diarrhea in a patient with lung adenocarcinoma.Metastatic Gastrointestinal Adenocarcinoma with Osteoblastic Activity: A Case Report of Esophageal and Colonic Primaries.Gastric Medullary Carcinoma with Sporadic Mismatch Repair Deficiency and a TP53 R273C Mutation: An Unusual Case with Wild-Type BRAF.Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study.Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease.Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. Authors' reply.Reproducibility of histological assessments of disease activity in UC.Caveolin-1 is not required for murine intestinal cholesterol transport.Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse.Biallelic Mismatch Repair Deficiency in an Adolescent FemaleDrug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient.Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mousePanniculitis in alpha-1 antitrypsin deficiency treated with enzyme replacementAssessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US
P50
Q30364476-4526155F-D020-4821-9F7E-ACB4F23ECBDAQ30413592-763C2ED4-C898-4BAC-BA82-1C8FAE739CBDQ30418856-2CA202AE-9D39-4B24-9DCD-BB4BA914F0F6Q30803684-EBA6B0A0-98BA-4ED3-8C5B-FDF5DBA5D0C3Q33721830-82F26FA9-6008-4B5D-AE60-BD0AE3E12A84Q33773208-D0A929BA-EFDA-4E87-944B-1AF41E1AFA73Q34357426-86539B8F-6665-4E02-96D4-E7663A910B63Q35985007-E58FC3A6-A2D8-4EC6-84C4-1E4FFF7BB63FQ36569181-ED8E3FAD-7355-43A2-8A6A-62901CEC19CFQ36956116-55E018B2-FDAC-4682-AC9E-360A51E6AB08Q37340339-9BFFFFA8-4794-4922-9CA1-E183B66BD036Q37583600-BF35123E-1425-4DF9-AF63-32853EA8A172Q37707904-EBA16D37-2E17-469F-BA7D-C58953CC50FAQ38511088-3E38AB61-E802-4802-82C3-D5BC53517E68Q39697982-131172E5-9FC1-4E72-A9B6-A05A6EDAAEA5Q39870631-6FB6425F-FD81-44E7-A5F8-097011F2735FQ39961975-AC3E5472-D73A-4329-A07A-3E71AAA2C93AQ40729003-221ABBE4-D824-493D-8E88-6B7D57DB1AFCQ41376190-EEAE892F-93C5-4E08-92F6-3D52C13BE567Q41439550-690524B2-C258-4E56-9240-BB23A917685FQ41605338-CB777D97-DB05-47DD-95E5-205D09F134EAQ41633785-0ED49612-F9B4-4950-B21C-8DBF13D03FC5Q42718504-3D51A65F-D287-4727-891C-AF437A63389DQ46220664-69486808-0F9E-4D60-B0F4-65B3A6F1F08BQ46375131-66A28654-5C34-4943-902A-A8787F588A35Q46513036-299C54A1-2C05-4240-B2D4-A79F022B6341Q46832187-9CA0D8F7-EBDB-40C4-A961-2E2E8417A65DQ57646262-207BBAEB-9B5F-4C11-999B-20CC41772790Q64976467-4E4F8F99-6A63-4B0B-8AC7-F069C894DC07Q80860475-B927518E-FE9B-47D1-ABB0-09F2987E3BF6Q83661218-776710CF-B16D-4066-A44C-1927044D5F2AQ89513439-CE7C7FB4-B137-4407-83BD-7C3683707B34
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-1721-3451
@en
name
Mark A Valasek
@ast
Mark A Valasek
@en
Mark A Valasek
@es
Mark A Valasek
@nl
type
label
Mark A Valasek
@ast
Mark A Valasek
@en
Mark A Valasek
@es
Mark A Valasek
@nl
prefLabel
Mark A Valasek
@ast
Mark A Valasek
@en
Mark A Valasek
@es
Mark A Valasek
@nl
P106
P1153
8689030400
P31
P496
0000-0003-1721-3451